Is baclofen indicated for treating a spasmodic cough?

Baclofen is NOT indicated for spasmodic cough

Baclofen is FDA-approved exclusively for spasticity from multiple sclerosis and spinal cord diseases—not for cough. 1 The FDA label explicitly states baclofen "is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders" and makes no mention of cough as an approved indication. 1

Why This Matters

You're likely asking about baclofen because someone has chronic refractory cough with spasmodic features. While baclofen has shown some promise in research settings for chronic unexplained cough, the CHEST guidelines recommend gabapentin—not baclofen—as the neuromodulator of choice for unexplained chronic cough. 2

The Evidence Hierarchy

What Guidelines Actually Recommend:

The 2016 CHEST guidelines for unexplained chronic cough make a Grade 2C recommendation for gabapentin (starting 300 mg daily, titrating to maximum 1,800 mg/day in divided doses), with explicit discussion of risks and benefits. 2

Baclofen is not mentioned in these guidelines as a recommended treatment.

Research on Baclofen for Cough:

While several small studies suggest baclofen may help chronic refractory cough:

• A 2013 study showed 56.3% response rate in refractory GERD-induced cough (12 patients) 3
• A 1998 case report showed improvement in 2 patients with chronic refractory cough 4
• A 2016 meta-analysis pooled baclofen with other neuromodulators, showing promise but acknowledging methodological limitations 5

However, these are small studies with significant limitations, and none establish baclofen as standard therapy.

Clinical Algorithm

If you're facing a patient with spasmodic/chronic cough:

1. First: Complete guideline-based workup including objective testing for bronchial hyperresponsiveness and eosinophilic bronchitis 2

2. If unexplained chronic cough persists:

   • First-line neuromodulator: Gabapentin (Grade 2C recommendation) 2
   • Also consider: Multimodality speech pathology therapy (Grade 2C) 2

3. Baclofen considerations: Only if gabapentin fails or is contraindicated, and only as off-label use with informed consent about:

   • Sedation risk (major concern—can impair driving/activities) 1
   • CNS depression additive with alcohol/other CNS depressants 1
   • Typical research dose: 20 mg three times daily 3
   • No established dosing guidelines for cough

Critical Safety Concerns

Baclofen carries significant risks that make it a poor choice without compelling evidence:

• Sedation and CNS depression are common 1
• Severe withdrawal syndrome can occur with abrupt discontinuation (psychiatric disturbances, delirium, autonomic instability within 1-4 days) 6
• Toxicity at doses ≥300 mg/day causes CNS depression (68%), seizures (36%), respiratory depression (21%) 6

Bottom Line

Use gabapentin, not baclofen, for chronic unexplained cough with spasmodic features. Gabapentin has guideline support, established dosing for cough, and a better risk-benefit profile. Baclofen remains an off-label, second-line option at best, reserved for cases where gabapentin has failed and the patient understands they're receiving a medication outside its approved indication with limited supporting evidence.